Comment
Author: Admin | 2025-04-28
IMPRINT: M 15 SHAPE: round COLOR: blue All Imprints morphine sulfate 30 mg - m 30 round purple morphine sulfate 15 mg - m 15 round blue morphine sulfate tablet, extended release - m 15 round blue morphine sulfate tablet, extended release - m 30 round purple morphine sulfate 60 mg extended release oral tablet - m 60 round orange morphine sulfate tablet, extended release - m 100 round grey morphine sulfate 200 mg - m 200 oval green morphine sulfate 60 mg - m 60 round orange morphine sulfate 100 mg - m 100 round grey Boxed Warning Warning: Serious And Life-threatening Risks From Use Of Morphine Sulfate Extended-release Tablets Addiction, Abuse, and Misuse Because the use of morphine sulfate extended-release tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of morphine sulfate extended-release tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of morphine sulfate extended-release tablets are essential. Instruct patients to swallow morphine sulfate extended-release tablets whole; crushing, chewing, or dissolving morphine sulfate extended-release tablets can cause rapid release and absorption of a potentially fatal dose of morphine [see Warnings and Precautions (5.2)]. Accidental Ingestion Accidental ingestion of even one dose of morphine sulfate extended-release tablets, especially by children, can result in a fatal overdose of morphine [see Warnings and Precautions (5.2)]. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of morphine sulfate extended-release tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)]. Neonatal Opioid Withdrawal Syndrome (NOWS) If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)]. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS-compliant education program, and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)]. WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM
Add Comment